Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 04, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase price of 1,307.9396 pence per share.
Material Changes
- Share Repurchase: On September 04, 2007, the company purchased 1,280,000 ordinary shares of 25 pence each.
- Treasury Holdings: Following this transaction, the company holds 379,107,158 shares in Treasury, representing 6.71% of total voting rights.
- Shares in Issue: The total number of shares in issue (excluding Treasury shares) is 5,643,315,890.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,643,315,890) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count (379,107,158) and its percentage of total voting rights (6.71%).
- Review the specific authorization from the May 23, 2007 Annual General Meeting regarding the share buyback program.